Reuters logo
Blackstone and Prestige eyeing GSK portfolio: report
September 20, 2011 / 2:35 AM / 6 years ago

Blackstone and Prestige eyeing GSK portfolio: report

(Reuters) - Blackstone (BX.N) is working with Prestige Brands of America to bid for a portfolio of GlaxoSmithKline (GSK.L) over-the-counter drugs in a deal worth up to 2 billion pounds ($3 billion), the Times reported on Tuesday.

The newspaper quoted a person close to the deal as saying that the bid was still in the “very early stages.”

Glaxo, Britain’s biggest drugmaker, has put up for sale several businesses marketing over-the-counter (OTC) products with combined revenue of around 500 million pounds.

Reporting by Kate Holton; Editing by Steve Orlofsky

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below